Gupta, D.L., Meher, J., Giri, A.K., Shukla, A.K., Mohapatra, E., Ruikar, M.M. and Rao, D. 2024. RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients. Drug Target Insights. 18, 1 (May 2024), 20–26. DOI:https://doi.org/10.33393/dti.2024.3059.